David M. Goldenberg Sells 40,000 Shares of Immunomedics, Inc. (IMMU) Stock
Immunomedics, Inc. (NASDAQ:IMMU) Director David M. Goldenberg sold 40,000 shares of the company’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $17.24, for a total transaction of $689,600.00. Following the completion of the transaction, the director now directly owns 1,774,285 shares of the company’s stock, valued at $30,588,673.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Immunomedics, Inc. (IMMU) opened at $16.94 on Wednesday. The firm has a market cap of $2,580.00, a price-to-earnings ratio of -9.11 and a beta of 1.48. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 1.26. Immunomedics, Inc. has a one year low of $5.00 and a one year high of $18.93.
Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.09). The business had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $0.90 million. analysts predict that Immunomedics, Inc. will post -0.96 earnings per share for the current year.
IMMU has been the subject of a number of research analyst reports. Jefferies Group upped their target price on shares of Immunomedics from $22.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, January 24th. BidaskClub raised shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 25th. ValuEngine raised shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Saturday, February 17th. Finally, TheStreet raised shares of Immunomedics from a “d” rating to a “c-” rating in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $19.00.
Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.